iBET

iBET participates in the recently EC-awarded project “TRANSVAC2”

19.04.2017

The European Commission has officially approved the “TRANSVAC2” project on February 1st 2017. This project, in which iBET and Genibet - Biopharmaceuticals, S.A. participate, has as coordinating institution the European Vaccine Initiative (EWIV) and a maximum grant amount of 10 M€ for 60 months. The full title of the project is “European Vaccine Research and Development Infrastructure” and will be focused on the establishment of a fully operational and sustainable European vaccine R&D infrastructure.

“TRANSVAC2” is the follow-up project to its successful predecessor project TRANSVAC, the European Network of Vaccine Research and Development funded under FP7. The “TRANSVAC2” consortium comprises a comprehensive collection of leading European institutions that propose to further advance with the previous initiative towards the establishment of a fully operational and sustainable European vaccine R&D infrastructure. “TRANSVAC2” will support innovation for both prophylactic and therapeutic vaccine development based on a disease-overarching and one-health approach, thereby optimising the knowledge and expertise gained during the development of both human and animal vaccines. This will be achieved by bridging the translational gap in biomedical research, and by supporting cooperation between public vaccine R&D institutions of excellence, related initiatives and networks in Europe, and industrial partners. “TRANSVAC2” will complement and integrate with existing European research infrastructures in both the public and private sectors. “TRANSVAC2” will function as leverage and innovation catalyst between all stakeholders involved in vaccine R&D in Europe and - by providing integrated and overarching vaccine R&D services - will contribute to the development of effective products to address European and global health challenges, to controlling the burden and spread of infectious diseases, and reinforce the economic assets represented by vaccine developers in Europe. The impact of “TRANSVAC2” will be maximised by two external advisory bodies. An independent Scientific & Ethics Advisory Committee will provide recommendations surrounding scientific-technical and ethical issues, whereas the coordination of “TRANSVAC2” with other related initiatives and the further promotion of the long-term stability of a European vaccine R&D infrastructure will be supported by a Board of Stakeholders comprising representatives of policy and decision makers, industry associations and European infrastructures.

The “TRANSVAC2” project is funded by European Commission under the H2020-INFRAIA-2016-2017 call (Integrating Activities for Advanced Communities).